Results 141 to 150 of about 432,951 (336)

Transmembrane potential of GlyCl-expressing instructor cells induces a neoplastic-like conversion of melanocytes via a serotonergic pathway

open access: yesDisease Models & Mechanisms, 2011
SUMMARY Understanding the mechanisms that coordinate stem cell behavior within the host is a high priority for developmental biology, regenerative medicine and oncology.
Douglas Blackiston   +4 more
doaj   +1 more source

A Bifunctional Small Molecule Degrader of the Long Noncoding RNA MALAT1 Triplex

open access: yesChemistry – A European Journal, EarlyView.
Targeting disease‐linked RNAs with small molecules is often limited by the modest impact of binding RNA structure alone. Here, we present a first‐in‐class bifunctional molecule that degrades the oncogenic lncRNA MALAT‐1 by inducing proximity between the RNA and a cleaving warhead.
Christian A. T. Brega   +11 more
wiley   +1 more source

Evolution of the AGMK1-9T7 GLI1+ progenitor cells to become tumor cells and potentially cancer-stem cells

open access: yesAdvances in Cancer Biology - Metastasis
We have investigated the expression of selected genes and miRNAs that have been found to be associated with human cancer-stem cells for their involvement in the neoplastic evolution of our AGMK1-9T7 cell line from a non-tumorigenic status at passage (p ...
Andrew M. Lewis, Jr.   +7 more
doaj   +1 more source

Immortalization without neoplastic transformation of human mesenchymal stem cells by transduction with HPV16 E6/E7 genes [PDF]

open access: bronze, 2004
Shih‐Chieh Hung   +6 more
openalex   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Imaging Flow Cytometry Detection of Cytogenetic Abnormalities in Circulating CD34+ Cells Predicts Leukemic Transformation in Myelofibrosis

open access: yesCytometry Part A, EarlyView.
ABSTRACT Myelofibrosis is a myeloproliferative neoplasm with potential to transform to acute myeloid leukemia. This evolution is unpredictable and current assays lack the sensitivity and applicability needed to predict this transformation. While population‐level data utilizing comprehensive genomic profiling can identify subgroups at higher risk of ...
Ruby M. Hamilton   +8 more
wiley   +1 more source

Hemangioblastomas might derive from neoplastic transformation of neural stem cells/progenitors in the specific niche [PDF]

open access: bronze, 2010
Dexuan Ma   +6 more
openalex   +1 more source

Analysis of SWI Complex Subunits in 69 Cases of TTF‐1 Negative Non‐Small Cell Lung Carcinoma

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Non‐small cell lung carcinomas, not otherwise specified (NSCLC‐NOS) with a specific signature including high‐grade hepatoid/clear cell morphology, negative lung panel mutational analysis, negative TTF‐1/Napsin A staining can be reported as a morphologic variant of an aggressive carcinoma with loss of one of the subunits of the SWI/SNF ...
Ramin Zargham   +2 more
wiley   +1 more source

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy